Amgen Inc.: dividend

AMGNNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$465.67

November 13, 2026Market cap $251B

What Ploutos Investor adds for Amgen

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Yield

2.13%

$9.94 per share over the last 12 months, at a price of $465.67.

Forward yield2.16%($2.52 a quarter)

FCF coverThe year's free cash flow was 1.8 times the dividend it paid.
1.8x
Payout58% of the last 12 months' earnings went to the dividend.
58%
No cutWithout a cut since 2012, the first year of our figures: the run may be longer.
13+
5-year growthAverage yearly growth over the last five years.
+8.1%
Debt / EBITDAMoney that goes to interest does not go to the dividend.
2.3x

The dividend year by year

What it paid per share each fiscal year, how much that changed, and the yield it gave at the price at year end.

+8.1% a year over 5 years
  • 2025
    Dividend per share$9.66
  • 2024
    Dividend per share$9.13
  • 2023
    Dividend per share$8.64

Each fiscal year's dividend as the company states it in its filings, adjusted for stock splits. Special dividends count in the year they were paid.

The dividend year by year

AMGN's dividend per share each fiscal year, from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Everything it returns to shareholders

The dividend is one way. The other is buybacks, which reduce the number of shares.

Dividend yield

2.13%

$21.30 a year per $1,000 of shares

Buybacks

–

The share count rose by 0.4% over the year, so more shares were issued than bought back.

Total returned

2.13%

$21.30 a year per $1,000 of shares

AMGN beside the other dividend payers

Where it stands among this week's 968 dividend payers, and in the Healthcare sector. The dot is the company, the white line the median.

Dividend yield2.13%

Above 52% of the payers · median 2.03%

In Healthcare: above 77%, median 0.93%.

Covered by free cash flow1.8x

Above 23% of the payers · median 3.6x

In Healthcare: above 16%, median 4.4x.

Dividend growth, 5 years+8.1%

Above 63% of the payers · median +6.3%

In Healthcare: above 69%, median +5.8%.

Share of earnings paid out58%

Above 75% of the payers · median 35%

In Healthcare: above 81%, median 25%.

Yield, cover and years without a cut for almost 1,000 stocks, in one table.The table

The full analysis

What do Amgen's filings show?

The dividend is one part of Amgen's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about AMGN's dividend

Didn't find what you were looking for?

Ask us
What is AMGN's dividend yield?

Amgen paid $9.94 per share over the last 12 months. At a price of $465.67, that is a yield of 2.13%.

Does AMGN cover its dividend with the cash it makes?

Yes, over the last year. Amgen's free cash flow was 1.8 times the dividend it paid.

Has AMGN ever cut its dividend?

Amgen has not cut its dividend for 13+ years, in the 14 years of figures we hold.

How much has AMGN's dividend grown?

Amgen's dividend per share changed by +8.1% a year on average over the last five years.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.